MSTR
Strategy Inc
There isn't enough reported data to score MSTR yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
MSTR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Strong |
MSTR's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MSTR PE Valuation
MSTR has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MSTR Forward outlook
There aren't enough analyst estimates for MSTR to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MSTR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$57.71 | -374% |
| Q2 2026 | -$94.04 | -960% |
| Q1 2026 | -$36.99 | -$14.75 |
| Q4 2025 | -$15.23 | -$9.17 |
| Q3 2025 | $21.07 | +$23.35 |
| Q2 2025 | $10.93 | +$12.50 |
| Q1 2025 | -$22.24 | -$21.39 |
| Q4 2024 | -$6.06 | -330% |
MSTR has swung to a loss: it lost $57.71 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MSTR on earnings quality, reporting a profit while its opponent remains loss making.
MSTR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $125.4M | -2.5% |
| Q2 2026 | $122.4M | +6.9% |
| Q1 2026 | $124.3M | +12% |
| Q4 2025 | $123M | +1.9% |
| Q3 2025 | $128.7M | +11% |
| Q2 2025 | $114.5M | +2.7% |
| Q1 2025 | $111.1M | -3.6% |
| Q4 2024 | $120.7M | -3% |
MSTR's revenue has picked up after five years of holding roughly level: $125M last quarter, down 2.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16671% | +13648 points |
| Q2 2026 | -6808% | -19064 points |
| Q1 2026 | -11642% | -6310 points |
| Q4 2025 | -14185% | -13343 points |
| Q3 2025 | 3023% | +3396 points |
| Q2 2025 | 12256% | +12436 points |
| Q1 2025 | -5331% | -5155 points |
| Q4 2024 | -842% | -808 points |
MSTR has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MSTR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
MSTR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4M | +$15.1M |
| Q2 2026 | -$5.9M | +$31.1M |
| Q1 2026 | $13M | +$18.2M |
| Q4 2025 | -$22.2M | -$4.6M |
| Q3 2025 | -$11.1M | +$30.3M |
| Q2 2025 | -$37M | -$13M |
| Q1 2025 | -$5.1M | -119% |
| Q4 2024 | -$17.6M | -2204% |
MSTR has burned cash in six of the last eight quarters: −$11M over the past year, against −$71M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MSTR on cash generation, producing positive trailing cash flow while its opponent burns cash.
MSTR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +21% | +75.5M shares |
| 1 year | +36% | +113M shares |
| 3 years | +201% | +286M shares |
| 5 years | +328% | +328M shares |
| Available history | +314% | +325M shares |
MSTR has 428M diluted shares, up 36% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | $744,000 |
| Q3 2020 | $60.6M |
| Q2 2020 | $11.1M |
| Q1 2020 | $50.7M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over MSTR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MSTR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 1.2x | Healthy |
| Q3 2020 | -5.2x | Net Cash |
| Q2 2020 | -11.9x | Net Cash |
| Q1 2020 | -17.1x | Net Cash |
| Q4 2019 | -29.1x | Net Cash |
MSTR's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
MSTR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.4 | Neutral |
| Stochastic | 42.1 | Neutral |
MSTR's weekly RSI is 42 (neutral) and its Stochastic is 42 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MSTR PE vs Technology Sector
| Metric | MSTR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
MSTR has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MSTR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $141.2 | 19% below |
| 20 week MA | $123.6 | 7.4% below |
| 50 week MA | $138.1 | 17% below |
| 100 week MA | $235.9 | 52% below |
| 200 week MA | $168.2 | 32% below |
MSTR is in a downtrend: it's below all five of its weekly moving averages, and 32% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over MSTR on trend strength, trading above more of its moving averages.
MSTR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.5 | $32.3 | +123% |
| 2021 | $32.3 | $59.7 | +85% |
| 2022 | $59.7 | $16.3 | -73% |
| 2023 | $16.3 | $63.2 | +288% |
| 2024 | $63.2 | $330.0 | +422% |
| 2025 | $330.0 | $158.8 | -52% |
| 2026 YTD | $158.8 | $114.4 | -28% |
MSTR's yearly returns have swung widely, from +422% in 2024 to −73% in 2022. It's down 28% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MSTR on returns for 2026, with the stronger performance.